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Total mutation burden (TMB) is an aggregate genomic metric from somatic mutational data. 
The usage of TMB as a predictive biomarker of response to immunotherapy has been 
recently proposed but remains a contentious topic. Most of the previous works on TMB has 
focused on predicting checkpoint blockade response, but few have properly evaluated TMB 
as a prognostic factor. However, it is critical to understand any prognostic aspects of a 
biomarker before characterizing them as predictive biomarker to a specific therapeutic 
indication. 
In this study, we analyzed curated clinical and survival outcome data from The Cancer 
Genome Atlas (TCGA) and corresponding somatic mutation data from the Multi-Center 
Mutation Calling in Multiple Cancers (MC3) project. We characterized a variety of mutation 
burden metrics on patient outcome using Inverse Probability Treatment Weighted (IPTW) 
Cox Proportional-Hazards model. We also combined the logic and analytics of the Cox 
Proportional-Hazards model with neural networks to explore if complex non-monotonic 
relationships between mutational burden estimated and patient outcome were present. 
Our results show the associations between mutation burden and outcome, with both 
positive and negative effects of higher TMB observed depending on the tumor type. For 
iii 
 
most tumor types, the results from our neural network models were congruent with the 
results from the conventional Cox modeling in that generally monotonic relationships were 
observed. However, we identified a few tumor types in which clear non-monotonic 
relationships existed, which could not be adequately characterized by conventional Cox 
modeling of these data. 
In conclusion, the associations between mutation burden and outcome are tumor-specific, 
with both positive and negative effects of higher TMB observed depending on the tumor 
type. Understanding this background prognostic effect is critical in characterizing the utility 
of these metrics at predicting response to any given therapeutic intervention. Additionally, 
some tumor types exhibited non-monotonic relations between mutation burden metrics 
and outcome, stressing the importance of better understanding the nature of the prognostic 
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Total mutation burden (TMB) is an aggregate genomic metric from somatic mutational data. 
It is a quantitative measure of the total number of somatic mutations (usually qualified by 
some characteristic, such as non-synonymous mutations) found in a cancer cell’s genome 
relative to the total number megabase pairs (Mbp) examined. This reflects the accumulation 
of somatic mutations over the tumor’s lifetime, including both passenger along with driver 
mutations. Somatic mutations include but are not limited to in-frame insertion/ deletion, 
frameshift insertion/ deletion, missense mutation, nonsense mutation, and non-stop 
mutation. In most studies, the total number of coding mutations is normalized by the size of 
the exome (roughly 33 Mbps). 
Other aggregate genomic metrics include biomarkers such as Microsatellite Instability (MSI) 
and other mutational signatures. MSI is characterized by changes in the lengths of 
representative elements in the genome at well-known loci; mutational signatures are 
generally defined by distinguishing mutation processes that involves unique components of 
DNA repair, replication, destruction, or modification.1  
The usage of TMB as a predictive biomarker of response to immunotherapy has been 
recently proposed but remains a contentious topic. Studies have shown that higher TMB is 
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associated with better response to checkpoint inhibition treatment in several cancer 
types.2-6 Additionally, patients with higher frameshift burden were also shown to have better 
checkpoint inhibitor response.7 Moreover, the Food and Drug Administration (FDA) 
approved pembrolizumab treatment - a PD-1 inhibitor - for patients with high TMB in solid 
tumors. Higher TMB was defined in that study as greater than 10 TMB per Mbp as assessed 
from a gene panel assay only covering a small fraction of the exome.8 Most of the previous 
works on TMB has focused on predicting checkpoint blockade response; but few have 
properly evaluated TMB as a prognostic factor. However, it is critical to understand any 
prognostic aspects of a biomarker before characterizing them as predictive biomarker to a 
specific therapeutic indication. 
To characterize the prognostic effect of TMB, we performed survival analysis using clinical 
and molecular data obtained from The Cancer Genome Atlas (TCGA). TCGA contains 11,160 
molecular profiles of tumor samples across 33 cancer types, with patient demographics and 
follow-up information for most cases.9 Most of these cases represent early to middle stages 
of disease with effectively none of these cases having been treated with contemporary 
checkpoint blockade. As such the TCGA cohort is well suited to characterize the prognostic 




To assess the potential of TMB as a prognostic factor, we used Cox Proportional-Hazards 
model to evaluate the association between TMB and clinical endpoints. Cox Proportional 
Hazards-model is a regression model widely used in clinical research for investigating the 
relation between patient survival time and one or more covariates. It has been a valid 
cornerstone of survival-outcome correlative analysis. To enhance this model, we combined 
the flexibility of neural networks with Cox Proportional-Hazards model to identify more 
complex relationships (such as non-monotonic relationships) without requiring a priori 







Study Design  
Curated and filtered clinical and survival outcome data were obtained from The Cancer 
Genome Atlas Pan (TCGA). TCGA contains molecular profiles of tumors from 11,160 patients 
across 33 cancer types, and includes demographics and four major clinical outcome 
endpoints: overall survival (OS), progression-free interval (PFI), disease-free interval (DFI), 
and disease-specific survival (DSS).9  
Somatic mutation data that corresponds with the TCGA data were obtained from the 
Multi-Center Mutation Calling in Multiple Cancers (MC3) project. The MC3 project 
developed unified pipelines for variant calling and filtering methods to ensure quality and 
consistency. An extensive compilation of somatic mutation calls for the TCGA data were 
generated, which contains 10,295 tumor-normal pairs from 33 cancer types, with 3,600,963 
produced somatic variants.10 
We observed that some tumors with different histological characteristics were merged into 
one TCGA tumor type code. For example, Infiltrating Ductal Carcinoma and Infiltrating 
Lobular Carcinoma were both categorized into Breast Invasive Carcinoma (BRCA), while they 
do not share the same histological and clinical features.11 For a closer reflection of tumor 
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biology, we re-labeled the tumor types using terminologies of National Cancer Institute 
Thesaurus (NCIt). [Appendix I: TCGA-NCIt corresponding table]  
Of the 11,160 TCGA patient data, we excluded some records using the following criteria: (1) 
patient records that lacked information for NCIt re-labeling; (2) patient records that were not 
in the MC3 data; (3) patient records with incomplete clinical outcome endpoints (missing OS, 
OS time, PFI, or PFI time). Also, for the validity of outcome data analyses, we only included 
NCIt-labeled tumors with patient numbers higher than 100 and median follow-up time 
longer than 1 year (specifically 365 days). This criteria at the NCIt tumor type level filtered 
out the following (NCIt code in parentheses): Testicular Seminoma (C7328), Testicular 
Non-Seminomatous Germ Cell Tumor (C9313), Esophageal Adenocarcinoma (C4025), 
Pancreatic Carcinoma (C3850), Cervical Adenosquamous Carcinoma (C4519), Liposarcoma 
(C3194), Leiomyosarcoma (C3158), Mesothelioma (C3234), Cholangiocarcinoma (C4436), 
Breast Carcinoma (C4872), Endometrial Mixed Cell Adenocarcinoma (C40153), Thyroid Gland 
Follicular Carcinoma (C8054), Cervical Adenocarcinoma (C4029), Myxofibrosarcoma (C6496), 
Undifferentiated Pleomorphic Sarcoma (C4247), Synovial Sarcoma (C3400), Prostate 
Adenocarcinoma (C2919), Diffuse Large B-Cell Lymphoma (C8851), Esophageal Squamous 
Cell Carcinoma (C4024), Chromophobe Renal Cell Carcinoma (C4146), Uterine 
Carcinosarcoma (C42700), Adrenal Cortex Carcinoma (C9325), Paraganglioma (C3308), 
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Malignant Peripheral Nerve Sheath Tumor (C3798), Desmoid-Type Fibromatosis (C9182), and 
Uveal Melanoma (C7712).  
After the selection criteria were applied, there were a total 8670 remained included patients 
across 25 NCIt tumor types, as listed below (NCIt code in parentheses): Adenocarcinoma, 
Pancreas (C8294), Astrocytoma (C60781), Cervical Squamous Cell Carcinoma (C4028), Clear 
Cell Renal Cell Carcinoma (C4033), Colorectal Adenocarcinoma (C5105), Cutaneous 
Melanoma (C3510), Endometrial Endometrioid Adenocarcinoma (C6287), Endometrial 
Serous Adenocarcinoma (C27838), Gastric Adenocarcinoma (C4004), Glioblastoma (C3058), 
Head and Neck Squamous Cell Carcinoma (C34447), Hepatocellular Carcinoma (C3099), 
Infiltrating Ductal Breast Carcinoma (C4194), Invasive Lobular Breast Carcinoma (C7950), 
Lung Adenocarcinoma (C3512), Lung Squamous Cell Carcinoma (C3493), Muscle-Invasive 
Bladder Carcinoma (C150572), Oligoastrocytoma (C4050), Oligodendroglioma (C3288), 
Ovarian Serous Adenocarcinoma (C7550), Papillary Renal Cell Carcinoma (C6975), 
Pheochromocytoma (C3326), Prostate Acinar Adenocarcinoma (C5596), Thymoma (C3411), 






Using the MC3 somatic mutation data, we defined tumor mutation burden (TMB) as all 
identified variations; nonsynonymous (NonSyn) mutation as in-frame insertion/ deletion, 
frameshift insertion/ deletion, missense mutation, nonsense mutation, non-stop mutation, 
and RNA mutation; single nucleotide polymorphism (SNP) as missense mutation and 
nonsense mutation; and insertion-deletion (INDEL) mutation as in-frame insertion/ deletion 
and frameshift insertion/ deletion. All numbers of mutations were calculated per megabase 
pair (Mbp). Since all these data are derived from whole exome sequencing, these metrics 
were normalized by the size of the exome, which is approximately 33 Mbps.  
From the TCGA data, we selected OS and PFI as clinical outcome endpoints. OS was defined 
as the duration from diagnosis date to date of death of any cause. It was a more accurate 
endpoint indicated by TCGA, as the events were unambiguously defined by the date of 
patient death. PFI was defined as the duration from the diagnosis date to date of the first 
occurrence of a new tumor event (includes disease progression, locoregional recurrence, 
distant metastasis, new primary tumor, or death with tumor). It was the suggested clinical 
endpoint choice for most of the cancer types in TCGA data, as PFI required relatively shorter 
clinical follow-up time, and more events were recorded within the study period.9  
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Statistical Analysis  
To take account for the association between covariates and TMB, Propensity Score was 
produced from a generalized linear model. Following the two-step selection criteria of Wu 
et.al, potential covariates, including age, gender (male and female), and race (White, Black, 
Asian, and Others), were filtered for the model construction. For the univariate initial 
inclusion, a threshold of p < 0.2 was required. For the multivariate secondary inclusion, a 
threshold of p < 0.1 was required.12 Using the generated Propensity Score, an Inverse 
Probability of Treatment Weight (IPTW) was evaluated for individual patients to compute the 
impact of TMB to OS and PFI in the context of a model that can account for covariate of 
TMB. 
IPTW-weighted Cox Proportional-Hazards Model was then carried out to evaluate the impact 
of TMB to OS and PFI. Similar analyses were executed to assess the impact of NonSyn/ SNP/ 
INDEL to patient outcome (OS/ PFI).  
By the result of Cox Proportional-Hazards model, we classified the tumor types into three 
groups based on the 90% confidence interval and the effect of increased mutations counts 
on the clinical endpoints (OS and PFI): positive effect (better outcome with increased 
mutation counts), negative effect (worse outcome with increased mutation counts), and no 
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significant association observed for tumor types that had confidence intervals crossing 1 (the 
line of no difference).  
Neural Network  
We used a simple 3 layer fully connected network that outputs a hazard score. The input 
layer into that final output layer of the network is interpreted as a vectors of predictors and 
the cox proportion hazard model is applied therein in which the loss function to be 
minimized is the negative log partial likelihood of the Cox model.13 In this manner, which the 
model can characterize potential non-monotonic relationships between in input scalar 
measure, such as TMB, and survival measures. 
We identified putative examples of such non-monotonic relationships in Endometrial 
Endometrioid Adenocarcinoma, Head and Neck Squamous Cell Carcinoma, and Lung 
Squamous Cell Carcinoma by examining the curvature of the neural network hazard output 
score across a range of input TMB. 
For each tumor, we separate patients into three groups by the Hazard Ratio output of the 
Neural Network model, and verified the sufficiency of patient numbers in each group. The 
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Kaplan Meier method was then performed, combined with p value computed by log-rank 
test to validate the non-monotonic relation between TMB and OS in actual patient data.  
In this study, we carried out data manipulation and statistical analyses using R version 3.6.0. 







After the tumor type selection criteria were applied, 8670 patients across 25 NCIt tumor 
types were included in this study. The patient demographics of included and excluded tumor 
types along with the aggregate mutation metrics (TMB/ NonSyn/ SNP/ INDEL) by each NCIt 
tumor type were shown in Appendix II and III. The median of TMB count ranged from 14 
(0.42 per Mbp) of Pheochromocytoma to 692 (20.97 per Mbp) of Cutaneous Melanoma; the 
median of NonSyn count ranged from 9 (0.27 per Mbp) of Pheochromocytoma to 415 (12.58 
per Mbp) of Cutaneous Melanoma; the median of SNP count ranged from 8 (0.24 per Mbp) 
of Pheochromocytoma to 401 (12.15 per Mbp) of Cutaneous Melanoma; last, the median of 
INDEL count ranged from 0 (0.00 per Mbp) of Pheochromocytoma and Thyroid Gland 
Papillary Carcinoma to 9 (0.27 per Mbp) of Endometrial Endometrioid Adenocarcinoma. 


















Figure 1 TMB, NonSyn, SNP, INDEL occurrence across 25 tumor types. The red dot in each 
violin plot indicates the median. 
The impact of the mutation metrics (TMB/ NonSyn/ SNP/ INDEL) to OS and PFI were 
evaluated separately by IPTW-weighted Cox Proportional-Hazards model. The hazard ratios 
for these various genomic predictors across 25 tumor types are shown in Figure 2A, 2B, 2C, 
and 2D for OS as the clinical endpoint, and Figure 3A, 3B, 3C, and 3D for PFI as the clinical 
endpoint. We were able to classify the tumor types into three groups based on the 90% 
confidence interval (CI) and the effect of increased mutations counts on the clinical 
endpoints (OS and PFI): positive effect (better outcome with increased mutation counts), 
negative effect (worse outcome with increased mutation counts), and no significant 
association observed for tumor types that had confidence intervals crossing 1 (the line of no 
difference). These strata were identified for each of the mutation counts we examined: TMB, 



















Figure 2. IPTW-weighted hazard ratios and 90% CI for the genomic predictors - TMB, NonSyn, 



















Figure 3. IPTW-weighted hazard ratios and 90% CI for the genomic predictors - TMB, NonSyn, 




For the relation between TMB and OS (Fig 2A), the positive effect group included 
Oligodendroglioma, Thyroid Gland Papillary Carcinoma, Astrocytoma, Hepatocellular 
Carcinoma, Muscle-Invasive Bladder Carcinoma, Ovarian Serous Adenocarcinoma, Gastric 
Adenocarcinoma, and Cutaneous Melanoma. Oligodendroglioma had the lowest Hazard 
Ratio 0.004782 (95% CI 0.000787 – 0.029066).   
The negative effect group included Clear Cell Renal Cell Carcinoma, Head and Neck 
Squamous Cell Carcinoma, Papillary Renal Cell Carcinoma, and Thymoma. Thymoma had the 
highest Hazard Ratio 40.98 (95% CI 6.298 – 266.662).  
The group of no significant association observed included Cervical Squamous Cell Carcinoma, 
Endometrial Serous Adenocarcinoma, Endometrial Endometrioid Adenocarcinoma, Invasive 
Lobular Breast Carcinoma, Lung Squamous Cell Carcinoma, Oligoastrocytoma, Colorectal 
Adenocarcinoma, Lung Adenocarcinoma, Infiltrating Ductal Breast Carcinoma, Glioblastoma, 
and Adenocarcinoma, Pancreas, and Prostate Acinar Adenocarcinoma. 
To further explore whether more complex relationships might exist between these mutation 
metrics and clinical endpoints, we performed the neural network model. The Hazard Ratio 
output of the model across 25 tumor types are shown in Figure 4A, 4B, 4C, 4D for OS as the 
clinical endpoint, and Figure 5A, 5B, 5C, 5D for PFI as the clinical endpoint. Most of the 
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tumors demonstrated monotonicity between the mutation counts and clinical outcome – 
either positive or negative effect - which is consistent with the outcome of the conventional 
Cox Proportional-Hazards model. However, some of the tumors exhibited non-monotonic 
relation between the mutation counts and clinical outcome. For example, of the impact on 
OS, Endometrial Endometrioid Adenocarcinoma, Head and Neck Squamous Cell Carcinoma, 
and Lung Squamous Cell Carcinoma displayed positive relation in lower TMB, negative 
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Figure 4. Hazard Ratio output of the neural network model across 25 tumor types for OS as 
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Figure 5. Hazard Ratio output of the neural network model across 25 tumor types for PFI as 




The identified tumors were then separately being examined and stratified into three groups 
by the predicted Hazard Ratios: low TMB, middle TMB, and high TMB. Among the three 
identified tumors with non-monotonic relation between TMB and OS, Lung Squamous Cell 
Carcinoma did not include sufficient patients in low and high TMB group (Fig 6C), while 
Endometrial Endometrioid Adenocarcinoma and Head and Neck Squamous Cell Carcinoma 
had valid number of patients in each group (Fig 6A, 6B). We then used the Kaplan Meier 
method accompanied with log-rank test for p value to analyze survival probability of the 
three groups. In Endometrial Endometrioid Adenocarcinoma, the middle TMB group has 
significantly lower (p value = 0.008) survival probability than low and high TMB group 
combined (Fig 7A). In Head and Neck Squamous Cell Carcinoma, the middle TMB group also 
demonstrated significantly lower (p value = 0.002) survival probability than low and high 





A. Endometrial Endometrioid Adenocarcinoma 
 
 
B. Head and Neck Squamous Cell Carcinoma 
 
 
C. Lung Squamous Cell Carcinoma 
 
Figure 6. Hazard Ratio output (the impact of TMB to OS) by neural network model and 




A. Endometrial Endometrioid Adenocarcinoma 
 
 
B. Head and Neck Squamous Cell Carcinoma 
 
Figure 7. The Kaplan-Meier plots show the survival probability curves of low TMB, middle 
TMB, and high TMB groups in 5 years. *The p values of log-rank test showing combined low 






In this study, we characterized a variety of mutation burden metrics on patient outcome. We 
analyzed curated clinical and survival outcome data from TCGA and corresponding somatic 
mutation data from the MC3 project. The TCGA tumor codes were re-labeled to better 
reflect clinically relevant groupings. For example, the histological subtypes of Breast Cancer - 
Infiltrating Ductal Carcinoma and Infiltrating Lobular Carcinoma - were both being 
categorized into Breast Invasive Carcinoma (BRCA) in TCGA data, while they differ in various 
histological, clinical, and radiographical features.11,14 By leveraging the established ontology 
of the NCIt, we allow for more salient and clinically relevant conclusions to be drawn from 
the data. 
A variety of mutation burden metrics and estimates have been proposed by some as 
biomarkers that can be used to predict the likelihood of response to checkpoint blockade 
immunotherapy across a variety of tumor types. However, we stress that without a baseline 
understanding of the underlying prognostic value of a biomarker, one cannot properly 
characterize its predictive nature. Our results from the IPTW-weighted Cox 
Proportional-Hazards Model highlight not only is it clear that there exists underlying 
prognostic information from these mutation burden metrics, but also that these effects are 
different across tumor types. In some tumor types, higher TMB counts were associated with 
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better outcomes (such as in Muscle-Invasive Bladder Carcinoma) while in other tumors 
higher TMB counts were associated with worse outcomes (such as in Clear Cell Renal Cell 
Carcinoma). The importance of these baseline characterization of prognostication in the 
context of a cohort (TCGA) not treated with checkpoint blockage immunotherapy cannot be 
over stressed. Consider, if the predictive effect of TMB in the context of an immunotherapy 
treated cohort is the same as what we observed in the TCGA, then it is very likely that in that 
context the biomarker is in fact not predictive of response to immunotherapy but rather 
represents a background prognostic information. Conversely, consider if the predictive effect 
of TMB in the context of immunotherapy were observed to be non-significant and its 
prognostic value in a non-immunotherapy treated cohort was shown to be correlated with 
worse outcome. One might false assume that it is not a biomarker of response/ benefit from 
immunotherapy, when it facts the opposite is true.  
Having attempted to characterize potential prognostic information encoded in these 
mutation burden estimates using conventional biostatistics tools, we then sought to explore 
the possibility of more complex relationships between mutation burden metrics and patient 
outcomes. We leveraged the flexibility of neural networks to be able to learning complex 
encoding of data as they have been in medical diagnosis, sequence analysis, and cancer drug 
mechanism prediction.15,16 We combined the logic and analytics of the Cox 
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Proportional-Hazards model with neural networks to explore if complex non-monotonic 
relationships between mutational burden estimated and patient outcome were present. For 
most tumor types, the results from our neural network model were congruent with the 
results from the conventional Cox modeling in that generally monotonic relationships were 
observed. However, intriguingly we identified a few tumor types in which clear 
non-monotonic relationships existed which could not be adequately characterized by 
conventional Cox modeling of these data. As was shown for Endometrial Endometroid 
Adenocarcinoma, patients whose tumors had either higher or lower TMB exhibited better 
outcomes, while intermediate levels of TMB correlated with worse outcomes. This may 
supported to some degree by the fact that two competing processes are in play in the 
biology here: (a) increased mutation rate may increase the likelihood of the tumor 
developing the ability to cause more severe disease (b) increased mutation rate may 
increase the likelihood of either altering a critical cellular system or generating a mutant 
form of a protein that would elicit an immune response.  
One limitation in our study is that we did not directly use the Inverse Probability Treatment 
Weight (IPTW) in the Neural Network model. But, rather just wanted to explore whether 
more complex relationships (non-monotonic) might exist between these metrics and 
outcome. We highlighted the findings in Endometrial Endometrioid Adenocarcinoma and 
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Head and Neck Squamous Cell Carcinoma; however, better characterization and validation 
are required in our future work. Additionally, this work is based on the TCGA whole exome 
data while the vast majority of clinical testing is done using focus gene panels that only 
cover 5-10% of the exome. More work will be required to ascertain how well these findings 
would translate to conventional gene panel-based testing.  
In conclusion, the associations between mutation burden and outcome are tumor-specific, 
with both positive and negative effects of higher TMB observed depending on the tumor 
type. Understanding this background prognostic effect is critical in characterizing the utility 
of these metrics at predicting response to any given therapeutic intervention. Additionally, 
some tumor types exhibited non-monotonic relations between mutation burden metrics 
and outcome, stressing the importance of better understanding the nature of the prognostic 
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TCGA histological type NCI-T Label NCI-T Code counts 
ACC Adrenocortical Carcinoma- Myxoid Type Adrenal Cortex Carcinoma C9325 1 
ACC Adrenocortical Carcinoma- Oncocytic Type Adrenal Cortex Carcinoma C9325 4 
ACC Adrenocortical carcinoma- Usual Type Adrenal Cortex Carcinoma C9325 87 
BLCA Muscle invasive urothelial carcinoma (pT2 or above) Muscle-Invasive Bladder Carcinoma C150572 409 
BLCA [Not Available]   3 
BRCA Infiltrating Carcinoma NOS Breast Carcinoma C4872 1 
BRCA Infiltrating Ductal Carcinoma Infiltrating Ductal Breast Carcinoma C4194 784 
BRCA Infiltrating Lobular Carcinoma Invasive Lobular Breast Carcinoma C7950 203 
BRCA Medullary Carcinoma Breast Carcinoma C4872 6 
BRCA Metaplastic Carcinoma Breast Carcinoma C4872 9 
BRCA Mixed Histology (please specify) Breast Carcinoma C4872 30 
BRCA Mucinous Carcinoma Breast Carcinoma C4872 17 
BRCA Other, specify Breast Carcinoma C4872 46 
BRCA [Not Available]   1 
CESC Adenosquamous Cervical Adenosquamous Carcinoma C4519 6 
CESC Cervical Squamous Cell Carcinoma Cervical Squamous Cell Carcinoma C4028 254 
CESC Endocervical Adenocarcinoma of the Usual Type Cervical Adenocarcinoma  C4029 6 
CESC Endocervical Type of Adenocarcinoma Cervical Adenocarcinoma  C4029 21 
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CESC Endometrioid Adenocarcinoma of Endocervix Cervical Adenocarcinoma  C4029 3 
CESC Mucinous Adenocarcinoma of Endocervical Type Cervical Adenocarcinoma  C4029 17 
CHOL Cholangiocarcinoma; distal Cholangiocarcinoma C4436 2 
CHOL Cholangiocarcinoma; hilar/perihilar Cholangiocarcinoma C4436 7 
CHOL Cholangiocarcinoma; intrahepatic Cholangiocarcinoma C4436 36 
COAD Colon Adenocarcinoma Colorectal Adenocarcinoma C5105 392 
COAD Colon Mucinous Adenocarcinoma Colorectal Adenocarcinoma C5105 62 
COAD [Discrepancy]   3 
COAD [Not Available]   2 
DLBC Diffuse large B-cell lymphoma (DLBCL) NOS (any anatomic site 
nodal or extranodal) 
Diffuse Large B-Cell Lymphoma C8851 41 
DLBC Primary DLBCL of the CNS Diffuse Large B-Cell Lymphoma C8851 3 
DLBC Primary mediastinal (thymic) DLBCL Diffuse Large B-Cell Lymphoma C8851 4 
ESCA Esophagus Adenocarcinoma, NOS Esophageal Adenocarcinoma C4025 89 
ESCA Esophagus Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma C4024 96 
GBM Glioblastoma Multiforme (GBM) Glioblastoma C3058 31 
GBM Treated primary GBM Glioblastoma C3058 20 
GBM Untreated primary (de novo) GBM Glioblastoma C3058 545 
HNSC Head & Neck Squamous Cell Carcinoma Head and Neck Squamous Cell Carcinoma C34447 517 
HNSC Head & Neck Squamous Cell Carcinoma Basaloid Type Head and Neck Squamous Cell Carcinoma C34447 10 
HNSC Head & Neck Squamous Cell Carcinoma, Spindle Cell Variant Head and Neck Squamous Cell Carcinoma C34447 1 
KICH Kidney Chromophobe Chromophobe Renal Cell Carcinoma C4146 113 
KIRC Kidney Clear Cell Renal Carcinoma Clear Cell Renal Cell Carcinoma C4033 537 
KIRP Kidney Papillary Renal Cell Carcinoma Papillary Renal Cell Carcinoma C6975 291 
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LAML  Acute Myeloid Leukemia C3171 200 
LGG Astrocytoma Astrocytoma C60781 194 
LGG Oligoastrocytoma Oligodendroglioma C3288 130 
LGG Oligodendroglioma Oligoastrocytoma C4050 191 
LIHC Fibrolamellar Carcinoma Hepatocellular Carcinoma C3099 3 
LIHC Hepatocellular Carcinoma Hepatocellular Carcinoma C3099 367 
LIHC Hepatocholangiocarcinoma (Mixed) Hepatocellular Carcinoma C3099 7 
LUAD Lung Adenocarcinoma Lung Adenocarcinoma C3512 522 
LUSC Lung Squamous Cell Carcinoma Lung Squamous Cell Carcinoma C3493 504 
MESO Biphasic mesothelioma Mesothelioma C3234 23 
MESO Diffuse malignant mesothelioma - NOS Mesothelioma C3234 5 
MESO Epithelioid mesothelioma Mesothelioma C3234 57 
MESO Sarcomatoid mesothelioma Mesothelioma C3234 2 
OV Serous Cystadenocarcinoma Ovarian Serous Adenocarcinoma C7550 587 
PAAD Pancreas-Adenocarcinoma Ductal Type Adenocarcinoma, Pancreas C8294 154 
PAAD Pancreas-Adenocarcinoma-Other Subtype Adenocarcinoma, Pancreas C8294 25 
PAAD Pancreas-Colloid (mucinous non-cystic) Carcinoma Pancreatic Carcinoma C3850 4 
PAAD Pancreas-Undifferentiated Carcinoma Pancreatic Carcinoma C3850 1 
PAAD [Discrepancy]   1 
PCPG Paraganglioma Paraganglioma C3308 18 
PCPG Paraganglioma; Extra-adrenal Pheochromocytoma Paraganglioma C3308 13 
PCPG Pheochromocytoma Pheochromocytoma C3326 148 
PRAD Prostate Adenocarcinoma Acinar Type Prostate Acinar Adenocarcinoma C5596 485 
PRAD Prostate Adenocarcinoma, Other Subtype Prostate Adenocarcinoma C2919 15 
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READ Rectal Adenocarcinoma Colorectal Adenocarcinoma C5105 151 
READ Rectal Mucinous Adenocarcinoma Colorectal Adenocarcinoma C5105 13 
READ [Not Available]   6 
SARC Dedifferentiated liposarcoma Liposarcoma C3194 59 
SARC Desmoid Tumor Desmoid-Type Fibromatosis C9182 2 
SARC Giant cell 'MFH' / Undifferentiated pleomorphic sarcoma with 
giant cells 
Undifferentiated Pleomorphic Sarcoma C4247 1 
SARC Leiomyosarcoma (LMS) Leiomyosarcoma C3158 105 
SARC Malignant Peripheral Nerve Sheath Tumors (MPNST) Malignant Peripheral Nerve Sheath 
Tumor 
C3798 9 
SARC Myxofibrosarcoma Myxofibrosarcoma C6496 25 
SARC Pleomorphic 'MFH' / Undifferentiated pleomorphic sarcoma Undifferentiated Pleomorphic Sarcoma C4247 29 
SARC Sarcoma; synovial; poorly differentiated Synovial Sarcoma C3400 2 
SARC Synovial Sarcoma - Biphasic Synovial Sarcoma C3400 2 
SARC Synovial Sarcoma - Monophasic Synovial Sarcoma C3400 6 
SARC Undifferentiated Pleomorphic Sarcoma (UPS) Undifferentiated Pleomorphic Sarcoma C4247 21 
SKCM  Cutaneous Melanoma C3510 470 
STAD Stomach Adenocarcinoma, Signet Ring Type Gastric Adenocarcinoma C4004 13 
STAD Stomach, Adenocarcinoma, Diffuse Type Gastric Adenocarcinoma C4004 72 
STAD Stomach, Adenocarcinoma, Not Otherwise Specified (NOS) Gastric Adenocarcinoma C4004 164 
STAD Stomach, Intestinal Adenocarcinoma, Mucinous Type Gastric Adenocarcinoma C4004 22 
STAD Stomach, Intestinal Adenocarcinoma, Not Otherwise Specified 
(NOS) 
Gastric Adenocarcinoma C4004 82 
STAD Stomach, Intestinal Adenocarcinoma, Papillary Type Gastric Adenocarcinoma C4004 8 
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STAD Stomach, Intestinal Adenocarcinoma, Tubular Type Gastric Adenocarcinoma C4004 79 
STAD [Discrepancy]   1 
STAD [Not Available]   2 
TGCT Non-Seminoma; Choriocarcinoma 
Non-Seminoma; Embryonal Carcinoma 
Non-Seminoma; Yolk Sac Tumor 
Non-Seminoma; Teratoma (Mature) 
Non-Seminoma; Teratoma (Immature) 
Testicular Non-Seminomatous Germ Cell 
Tumor 
C9313 1 
TGCT Non-Seminoma; Embryonal Carcinoma Testicular Non-Seminomatous Germ Cell 
Tumor 
C9313 15 
TGCT Non-Seminoma; Embryonal Carcinoma 
Non-Seminoma; Teratoma (Mature) 
Testicular Non-Seminomatous Germ Cell 
Tumor 
C9313 1 
TGCT Non-Seminoma; Embryonal Carcinoma 
Non-Seminoma; Teratoma (Mature) 
Non-Seminoma; Choriocarcinoma 
Non-Seminoma; Yolk Sac Tumor 
Seminoma; NOS 
Testicular Non-Seminomatous Germ Cell 
Tumor 
C9313 1 
TGCT Non-Seminoma; Embryonal Carcinoma 
Non-Seminoma; Teratoma (Mature) 
Non-Seminoma; Teratoma (Immature) 
Non-Seminoma; Yolk Sac Tumor 
Testicular Non-Seminomatous Germ Cell 
Tumor 
C9313 1 
TGCT Non-Seminoma; Embryonal Carcinoma 
Non-Seminoma; Yolk Sac Tumor 
Testicular Non-Seminomatous Germ Cell 
Tumor 
C9313 6 
TGCT Non-Seminoma; Embryonal Carcinoma Testicular Non-Seminomatous Germ Cell C9313 1 
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Non-Seminoma; Yolk Sac Tumor 
Non-Seminoma; Choriocarcinoma 
Tumor 
TGCT Non-Seminoma; Embryonal Carcinoma 
Non-Seminoma; Yolk Sac Tumor 
Non-Seminoma; Teratoma (Immature) 
Testicular Non-Seminomatous Germ Cell 
Tumor 
C9313 1 
TGCT Non-Seminoma; Embryonal Carcinoma 
Non-Seminoma; Yolk Sac Tumor 
Non-Seminoma; Teratoma (Mature) 
Testicular Non-Seminomatous Germ Cell 
Tumor 
C9313 1 
TGCT Non-Seminoma; Embryonal Carcinoma 
Non-Seminoma; Yolk Sac Tumor 
Non-Seminoma; Teratoma (Mature) 
Non-Seminoma; Teratoma (Immature) 
Seminoma; NOS 
Testicular Non-Seminomatous Germ Cell 
Tumor 
C9313 1 
TGCT Non-Seminoma; Embryonal Carcinoma 
Seminoma; NOS 
Testicular Non-Seminomatous Germ Cell 
Tumor 
C9313 2 
TGCT Non-Seminoma; Embryonal Carcinoma 
[Not Available] 
Testicular Non-Seminomatous Germ Cell 
Tumor 
C9313 1 




Testicular Non-Seminomatous Germ Cell 
Tumor 
C9313 1 
TGCT Non-Seminoma; Teratoma (Immature) Testicular Non-Seminomatous Germ Cell 
Tumor 
C9313 1 
TGCT Non-Seminoma; Teratoma (Immature) Testicular Non-Seminomatous Germ Cell C9313 1 
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Non-Seminoma; Teratoma (Mature) 
Non-Seminoma; Yolk Sac Tumor 
Tumor 
TGCT Non-Seminoma; Teratoma (Immature) 
Non-Seminoma; Yolk Sac Tumor 
Testicular Non-Seminomatous Germ Cell 
Tumor 
C9313 1 
TGCT Non-Seminoma; Teratoma (Immature) 
Non-Seminoma; Yolk Sac Tumor 
Non-Seminoma; Embryonal Carcinoma 
Testicular Non-Seminomatous Germ Cell 
Tumor 
C9313 1 
TGCT Non-Seminoma; Teratoma (Immature) 
Non-Seminoma; Yolk Sac Tumor 
Non-Seminoma; Embryonal Carcinoma 
Non-Seminoma; Teratoma (Mature) 
Testicular Non-Seminomatous Germ Cell 
Tumor 
C9313 1 
TGCT Non-Seminoma; Teratoma (Mature) Testicular Non-Seminomatous Germ Cell 
Tumor 
C9313 2 
TGCT Non-Seminoma; Teratoma (Mature) 
Non-Seminoma; Embryonal Carcinoma 
Non-Seminoma; Teratoma (Immature) 
Non-Seminoma; Yolk Sac Tumor 
Testicular Non-Seminomatous Germ Cell 
Tumor 
C9313 1 
TGCT Non-Seminoma; Teratoma (Mature) 
Non-Seminoma; Teratoma (Immature) 
Non-Seminoma; Embryonal Carcinoma 
Testicular Non-Seminomatous Germ Cell 
Tumor 
C9313 1 
TGCT Non-Seminoma; Teratoma (Mature) 
Non-Seminoma; Teratoma (Immature) 
Non-Seminoma; Embryonal Carcinoma 
Non-Seminoma; Yolk Sac Tumor 





TGCT Non-Seminoma; Teratoma (Mature) 
Non-Seminoma; Teratoma (Immature) 
Non-Seminoma; Yolk Sac Tumor 
Non-Seminoma; Embryonal Carcinoma 
Non-Seminoma; Choriocarcinoma 
Testicular Non-Seminomatous Germ Cell 
Tumor 
C9313 1 
TGCT Non-Seminoma; Teratoma (Mature) 
Non-Seminoma; Teratoma (Immature) 
Non-Seminoma; Yolk Sac Tumor 
Non-Seminoma; Embryonal Carcinoma 
Seminoma; NOS 
Testicular Non-Seminomatous Germ Cell 
Tumor 
C9313 2 
TGCT Non-Seminoma; Teratoma (Mature) 
Non-Seminoma; Yolk Sac Tumor 
Testicular Non-Seminomatous Germ Cell 
Tumor 
C9313 2 
TGCT Non-Seminoma; Teratoma (Mature) 
Seminoma; NOS 
Non-Seminoma; Embryonal Carcinoma 
Non-Seminoma; Yolk Sac Tumor 
Testicular Non-Seminomatous Germ Cell 
Tumor 
C9313 2 
TGCT Non-Seminoma; Teratoma (Mature) 
[Not Available] 
Non-Seminoma; Embryonal Carcinoma 
Non-Seminoma; Yolk Sac Tumor 
Testicular Non-Seminomatous Germ Cell 
Tumor 
C9313 1 
TGCT Non-Seminoma; Yolk Sac Tumor Testicular Non-Seminomatous Germ Cell 
Tumor 
C9313 3 
TGCT Non-Seminoma; Yolk Sac Tumor 
Non-Seminoma; Embryonal Carcinoma 





TGCT Non-Seminoma; Yolk Sac Tumor 
Non-Seminoma; Embryonal Carcinoma 
Non-Seminoma; Teratoma (Mature) 
Non-Seminoma; Teratoma (Immature) 
Testicular Non-Seminomatous Germ Cell 
Tumor 
C9313 1 
TGCT Non-Seminoma; Yolk Sac Tumor 
Non-Seminoma; Embryonal Carcinoma 
Non-Seminoma; Teratoma (Mature) 
Seminoma; NOS 
Testicular Non-Seminomatous Germ Cell 
Tumor 
C9313 1 
TGCT Non-Seminoma; Yolk Sac Tumor 
Non-Seminoma; Teratoma (Mature) 
Testicular Non-Seminomatous Germ Cell 
Tumor 
C9313 1 
TGCT Seminoma; NOS Testicular Seminoma C7328 64 
TGCT Seminoma; NOS 
Non-Seminoma; Choriocarcinoma 
Testicular Seminoma C7328 1 
TGCT Seminoma; NOS 
Non-Seminoma; Embryonal Carcinoma 
Testicular Seminoma C7328 1 
TGCT Seminoma; NOS 
Non-Seminoma; Teratoma (Mature) 
Testicular Seminoma C7328 1 
TGCT Seminoma; NOS 
Non-Seminoma; Teratoma (Mature) 
Non-Seminoma; Embryonal Carcinoma 
Testicular Seminoma C7328 1 
TGCT Seminoma; NOS 
Non-Seminoma; Teratoma (Mature) 
Non-Seminoma; Embryonal Carcinoma 
Non-Seminoma; Yolk Sac Tumor 
Testicular Seminoma C7328 1 
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TGCT Seminoma; NOS 
Non-Seminoma; Teratoma (Mature) 
Non-Seminoma; Teratoma (Immature) 
Non-Seminoma; Yolk Sac Tumor 
Testicular Seminoma C7328 1 
TGCT Seminoma; NOS 
Non-Seminoma; Yolk Sac Tumor 
Non-Seminoma; Embryonal Carcinoma 
Non-Seminoma; Teratoma (Immature) 
Testicular Seminoma C7328 1 
TGCT Seminoma; NOS 
Non-Seminoma; Yolk Sac Tumor 
Non-Seminoma; Teratoma (Mature) 
Non-Seminoma; Teratoma (Immature) 
Testicular Seminoma C7328 1 
THCA Other, specify   9 
THCA Thyroid Papillary Carcinoma - Classical/usual Thyroid Gland Papillary Carcinoma C4035 359 
THCA Thyroid Papillary Carcinoma - Follicular (>= 99% follicular 
patterned) 
Thyroid Gland Follicular Carcinoma C8054 102 
THCA Thyroid Papillary Carcinoma - Tall Cell (>= 50% tall cell features) Thyroid Gland Papillary Carcinoma C4035 37 
THYM Thymoma; Type A Thymoma C3411 15 
THYM Thymoma; Type AB Thymoma C3411 38 
THYM Thymoma; Type A 
Thymoma; Type AB 
Thymoma C3411 2 
THYM Thymoma; Type B1 Thymoma C3411 14 
THYM Thymoma; Type B1 
Thymoma; Type B2 
Thymoma C3411 1 
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THYM Thymoma; Type B2 Thymoma C3411 28 
THYM Thymoma; Type B2 
Thymoma; Type B3 
Thymoma C3411 3 
THYM Thymoma; Type B3 Thymoma C3411 12 
THYM Thymoma; Type C Thymoma C3411 11 
UCEC Endometrioid endometrial adenocarcinoma Endometrial Endometrioid 
Adenocarcinoma 
C6287 411 
UCEC Mixed serous and endometrioid Endometrial Mixed Cell Adenocarcinoma C40153 22 
UCEC Serous endometrial adenocarcinoma Endometrial Serous Adenocarcinoma C27838 115 
UCS Uterine Carcinosarcoma/ MMMT: Heterologous Type Uterine Carcinosarcoma C42700 20 
UCS Uterine Carcinosarcoma/ Malignant Mixed Mullerian Tumor 
(MMMT): NOS 
Uterine Carcinosarcoma C42700 24 
UCS Uterine Carcinosarcoma/MMMT: Homologous Type Uterine Carcinosarcoma C42700 13 
UVM Epithelioid Cell Uveal Melanoma C7712 13 
UVM Epithelioid Cell 
Spindle Cell 
Uveal Melanoma C7712 21 
UVM Spindle Cell Uveal Melanoma C7712 30 
UVM Spindle Cell 
Epithelioid Cell 






Appendix 2: Patient demographics of included tumor types 


















































































































































































































































































































































































































































































































































































































































































































































































































Appendix 3: Patient demographics of excluded tumor types 
 n age 
(median 
 IQR]) 
gender =  
F/ M (%) 
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